niceph casino login register

Artificial intelligence (AI) transitioned from a temporary trend to a widespread reality, gaining traction across industries due to its potential to enhance efficiency, generate revenue and create entirely new roles, yet concerns around its use and impact on jobs remained. Gone are the days when it was merely a buzzword; AI has now become an integral part of business strategy across various sectors. But its full impact on jobs is little known and so is the issue of intellectual property, data ownership and its privacy implications, and liability - who is liable if an accident or mishap occurs due to the use of AI. ET Year-end Special Reads Take That: The gamechanger weapon's India acquired in 2024 10 big-bang policy moves Modi government made in 2024 How governments tried to rein in the social media beast As technology becomes increasingly human-like and pervasive, organisations are now striving to unlock business value through innovative methods to engage customers and employees, enhance operational efficiencies, and generate new revenue streams, Wipro CIO Anup Purohit said. "We are working towards a future where AI is integrated seamlessly into everyday operations beyond the honeymoon period and into a mature phase," he said in an interaction with PTI. "This growth isn't confined to technology firms; conventional sectors like banking, finance, and healthcare are also progressively integrating AI to improve operational efficiency and boost customer engagement. "AI is no longer the flavour of the season but is now the reality at scale. It is gaining momentum across all business domains and sectors. Even those that were traditionally considered laggards like BFSI or healthcare are looking forward to embracing AI. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program "CIOs today are shifting their approach away from POC to executing initiatives at scale ... to turn the GenAI 'trend' into business value by solving real business problems and cutting out the noise while managing costs," Purohit said. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories However, Indian enterprises will need to scale AI by expanding the gamut beyond basic virtual assistants and predictive analytics to a combination of AI-tech-based scalable use cases, according to Nasscom . "With the global AI market valued at approximately $235 billion and projected to grow to over $631 billion by 2028, AI is redefining industries and economies. The possibilities seem endless, from predictive analytics in agriculture to personalised healthcare solutions. In addition, emerging technologies such as quantum computing and federated learning are poised to redefine the AI landscape and open new frontiers," Tech Mahindra COO Atul Soneja said. Agentic AI: The new frontier of Autonomous Intelligence The futuristic movies where technology takes over human tasks are set to become a reality in 2025, as an increasing number of enterprises adopt agentic AI to handle mundane and repetitive jobs. Arun Parameswaran, MD, Sales, Salesforce India, believes 2025 will mark the true dawn of agentic AI - a new era where AI systems move beyond being reactive assistants to becoming proactive, autonomous agents capable of transforming customer engagement, business efficiency, and decision-making. "We will witness AI agents working collaboratively, transforming productivity and redefining problem-solving at an unprecedented scale. The future will not just be about using AI; it will be about creating and customizing agents that collaborate to understand and execute strategic tasks and decisions, both in personal and business contexts," he said. AI agents will significantly enhance business processes by improving efficiency and customer service, Purohit said. Sky's the Limit: Cloud Computing soars alongside AI In addition to AI, cloud computing continues to gain traction. Major players like Amazon Web Services and Microsoft Azure are expanding their footprints in India, catering to the increasing demand for scalable and flexible IT solutions. This shift towards cloud services is enabling businesses to innovate rapidly and respond more effectively to market changes. According to research firm IDC, the overall Indian public cloud services market is expected to reach $ 24.2 billion by 2028, growing at a CAGR of 23.8 per cent for 2023-28. "The integration of AI with cloud services will allow companies to quickly scale their AI models, manage extensive datasets in real-time, and gain insights for smarter decision-making. "The combination of AI and cloud services will help businesses innovate more swiftly, respond to market changes with greater flexibility, and maintain a long-term competitive edge," Purohit said. Adapt or fade away: Upskilling essential amid AI boom The rapid evolution of technology is also reshaping the job landscape and demand for skilled talent is set to soar as AI continues to redefine job roles across sectors. "With the rapid deployment of AI-led solutions, the industry will soon witness a demand-supply gap of skilled talent. Future professionals will need to build deeper business and communications skills, such as listening, problem-solving, as well as specific domain expertise to leverage AI to solve complex business problems," Purohit said. Future professionals will need a robust blend of technical expertise and soft skills, including adaptability, emotional intelligence, and strong communication abilities. As businesses increasingly rely on AI-driven solutions, there will be a critical need for individuals who can bridge the gap between technology and business strategy. "AI/Gen AI will impact knowledge work (white-collar work) in ways that no prior technology has, and this is likely to cause significant and continuous shifts in knowledge work (the what) and ways of working (the how) for all businesses. All businesses will need to define work next-practices continually to remain competitive," TCS CTO Harrick Vin said in an interaction with PTI. Future roles will require greater levels of critical thinking, design, strategic goal setting, and creative problem-solving skills, he said. "This would mean different things in the context of various types of work. For example, for the domain of software DevOps, teams will start to de-prioritise basic scripting skills for infrastructure provisioning and configuration, low-level monitoring configurations and metrics tracking, and test automation, among others. Instead, they will focus more on product requirements analysis, definition of acceptance criteria, software and architectural design," Vin said. For professionals entering the tech industry in 2025, he listed three primary and most needed skills' -- Learning to learn; Critical thinking/analysis; and Techno-functional skills for applying computational thinking and methods to solve complex domain problems.niceph casino login register 。

HMRC warns 'you need to check this' to avoid 'large tax bill'Financial giants have made a conspicuous bearish move on NIO. Our analysis of options history for NIO NIO revealed 28 unusual trades. Delving into the details, we found 28% of traders were bullish, while 71% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $445,200, and 25 were calls, valued at $1,229,396. Expected Price Movements Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1.0 to $7.0 for NIO over the recent three months. Volume & Open Interest Trends Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in NIO's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to NIO's substantial trades, within a strike price spectrum from $1.0 to $7.0 over the preceding 30 days. NIO Option Volume And Open Interest Over Last 30 Days Biggest Options Spotted: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume NIO PUT TRADE BULLISH 01/16/26 $1.03 $1.0 $1.0 $4.00 $300.0K 105.2K 3.0K NIO CALL SWEEP BULLISH 06/20/25 $0.7 $0.68 $0.7 $6.00 $126.0K 9.5K 2.0K NIO CALL SWEEP BULLISH 06/20/25 $0.7 $0.68 $0.7 $6.00 $97.6K 9.5K 2.5K NIO PUT SWEEP BEARISH 04/17/25 $0.44 $0.42 $0.44 $4.00 $88.0K 44.8K 2.0K NIO CALL SWEEP BEARISH 02/21/25 $0.41 $0.4 $0.4 $5.00 $80.2K 42.4K 1.7K About NIO Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market. In light of the recent options history for NIO, it's now appropriate to focus on the company itself. We aim to explore its current performance. Current Position of NIO With a trading volume of 23,968,259, the price of NIO is up by 2.9%, reaching $4.61. Current RSI values indicate that the stock is may be approaching overbought. Next earnings report is scheduled for 70 days from now. Expert Opinions on NIO 1 market experts have recently issued ratings for this stock, with a consensus target price of $3.9. Unusual Options Activity Detected: Smart Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access .* Reflecting concerns, an analyst from Goldman Sachs lowers its rating to Sell with a new price target of $3. Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NIO options trades with real-time alerts from Benzinga Pro . © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Uttarakhand Shines at IFFI: New Film Policy Garners PraiseT-cell malignancies account for about 10-15% of all lymphoid malignancies, and their treatment often involves chemotherapy, immunotherapy, or stem cell transplantation. These cancers can be particularly challenging due to their heterogeneity and resistance to traditional treatments. LAS VEGAS , Dec. 11, 2024 /PRNewswire/ -- T-cell malignancies are a group of cancers originating from the T-cells, a vital part of the immune system responsible for recognizing and combating foreign invaders. These cancers can develop when T-cells undergo genetic mutations, leading to uncontrolled growth and division. T-cell malignancies are generally categorized into two broad types: T-cell lymphomas and T-cell leukemias. T-cell lymphomas primarily affect the lymphatic system, involving lymph nodes and other lymphoid tissues, while T-cell leukemias impact the blood and bone marrow. These malignancies are often more aggressive and harder to treat than B-cell cancers due to their complex biology and resistance to conventional therapies. Symptoms can vary but typically include enlarged lymph nodes, fever, night sweats, and weight loss. Treatment options include chemotherapy, radiation therapy, and novel therapies like CAR T-cell therapy and targeted therapies, which are advancing the understanding and management of these challenging cancers. DelveInsight has recently released a series of epidemiology-based market reports focusing on T-cell malignancies including Acute Lymphoblastic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma . These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2020 to 2034 segmented into 7MM [ the United States , the EU-4 ( Italy , Spain , France , and Germany ), the United Kingdom , and Japan ]. Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these T-cell malignancies markets individually. Acute Lymphocytic Leukemia Market Acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, is a cancer that develops in the blood and bone marrow. It originates from immature white blood cells known as lymphocytes in the bone marrow and is marked by the excessive production of immature cells, referred to as lymphoblasts or leukemic blasts. As the bone marrow fails to produce sufficient red blood cells, healthy white blood cells, and platelets, individuals with ALL are more prone to anemia, frequent infections, and easy bruising or bleeding. Among the 7MM, the US accounted for the highest number of incident cases of acute lymphocytic leukemia. The total incident cases of acute lymphocytic leukemia in the US comprised approximately 6,800 cases in 2023 and are projected to increase during the forecast period. Among the type-specific cases of acute lymphocytic leukemia, B-acute lymphocytic leukemia accounted for nearly 85% of the cases, while T-acute lymphocytic leukemia accounted for nearly 15% in the US. The treatment paradigms of acute lymphocytic leukemia have been revolutionized with the advent of tyrosine kinase inhibitors targeting BCR-ABL1 (GLEEVEC [imatinib mesylate], SPRYCEL [dasatinib], and ICLUSIG [ponatinib]), monoclonal antibodies targeting CD20 (RITUXAN), antibody-drug conjugates targeting CD22 (BESPONSA), bispecific antibodies (BLINCYTO), CD19 chimeric antigen receptor T cell therapy (KYMRIAH and TECARTUS) , and others. As per DelveInsight analysis, in 2023, the market size for acute lymphocytic leukemia across the 7MM was around USD 1.6 billion , with projections indicating further growth by 2034. The United States dominated the market in 2023, contributing approximately USD 1.2 billion . ALL presents a significant market opportunity, with BLINCYTO currently leading the segment. Amgen continues to drive innovation in ALL through its BiTE Technology, receiving FDA approval in June 2024 . Additionally, Amgen is advancing a registration-enabling study to develop a subcutaneous injection formulation of blinatumomab. Acute Lymphocytic Leukemia Pipeline Therapies and Companies Orca-T: Orca Biosystems AUTO1/22: Autolus Therapeutics VENCLEXTA/VENCLYXTO (venetoclax): AbbVie and Roche (Genentech) Daratumumab: J&J Innovative Medicine IMBRUVICA (ibrutinib): Pharmacyclics (an AbbVie Company) JAKAFI (ruxolitinib): Incyte Corporation/Novartis VYXEOS (CPX-351): Jazz Pharmaceuticals Obecabtagene autoleucel (obe-cel): Autolus Therapeutics SNDX-5613 (revumenib): Syndax Pharmaceuticals UCART22: Cellectis ADCT-602: ADC Therapeutics WU-CART-007: Wugen For a comprehensive view of the acute lymphocytic leukemia market, check out the Acute Lymphocytic Leukemia Market Assessment Peripheral T-cell Lymphoma Market Peripheral T-cell lymphoma represents a heterogeneous collection of aggressive lymphomas arising from mature T-cells and natural killer cells, comprising approximately 10–15% of all non-Hodgkin lymphomas globally. PTCL is more prevalent in Asia compared to North America and Europe . PTCL has been reported to account for 25% of all NHL cases in Japan . The increased rate of T-cell lymphomas in Asia is attributed to the low incidence of follicular lymphomas. The total incident cases of PTCL in the 7MM were 26,000 cases in 2023; these cases are estimated to increase by 2034. As more targetable mutations are identified and new targeted therapies are developed, the range of treatment options for patients and oncologists continues to expand. However, with the rapid pace of drug approvals, it is crucial to ensure that adequate supporting data justifies the use of specific therapies in the appropriate treatment settings, whether as adjuvant, consolidation, first-line, or subsequent treatments. Peripheral T-cell lymphoma remains a significant therapeutic challenge due to its aggressive nature, rarity, and high heterogeneity. Conventional chemotherapy for PTCL typically involves anthracycline-based regimens (such as CHOP and EPOCH) or non-anthracycline alternatives (including platinum, etoposide, gemcitabine, and methylprednisolone). While the majority of patients initially undergo chemotherapy, nearly a quarter develop primary refractory disease. Many others relapse even after responding to induction chemotherapy, with a median overall survival of just six months. According to NCCN guidelines, specific PTCL subtypes are also treated with six cycles of CHOP-21 or CHOEP, often combined with involved-site radiation therapy. The FDA has approved several drugs for PTCL treatment, including BELEODAQ (Belinostat, Acrotech Biopharma), ISTODAX (Romidepsin, Celgene), FOLOTYN (Pralatrexate, Acrotech Biopharma), ARRANON (Nelarabine, GlaxoSmithKline), XALKORI (Crizotinib, Pfizer), and ADCETRIS (Brentuximab Vedotin, Seattle Genetics). Until recently, there was no established standard of care for first-line treatment in PTCL, leaving a significant gap in approved therapies. The approval of ADCETRIS in November 2018 by the US FDA has transformed the treatment landscape. ADCETRIS, in combination with chemotherapy, is now the first and only FDA-approved regimen for first-line treatment of adults with previously untreated systemic ALCL or other CD30-expressing PTCL. Notably, its approval came less than two weeks after submission under the FDA's real-time oncology review pilot program. Key players, such as Secura Bio, HUYA Bioscience International, Verastem, Solasia Pharma, Seagen, Dizal Pharmaceutical , and others, are evaluating their lead candidates in different stages of clinical development, respectively. As per the DelveInsight assessment, the total market size in the 7MM for PTCL was estimated to be ~USD 680 million in 2020, which is projected to show positive growth by 2034. This growth of the PTCL market is expected to be mainly driven by increased diagnosed incidence, patient awareness, and a robust clinical pipeline during the forecast period (2024–2034). PTCL Pipeline Therapies and Companies COPIKTRA (duvelisib): Secura Bio Linperlisib (YY-20394): Shanghai YingLi Pharmaceutical Golidocitinib (DZD4205) : Dizal Pharmaceuticals Nanatinostat + Valganciclovir: Viracta Therapeutics Lacutamab/IPH4102: Innate Pharma Sugemalimab (CS1001): CStone Pharmaceuticals AFM13: Affimed Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals AUTO4: Autolus MT-101: Myeloid Therapeutics KEYTRUDA (pembrolizumab): Merck Sharp & Dohme OPDIVO (nivolumab): Bristol Myers Squibb To gain a deeper understanding of the PTCL market, be sure to explore the Peripheral T-cell Lymphoma Market Outlook Cutaneous T-cell Lymphoma Market Cutaneous T-cell lymphomas are rare cancers that predominantly involve the skin. Some types progress slowly within the skin, while others may spread to the blood or lymph nodes. The most prevalent form of CTCL is mycosis fungoides, along with its leukemic variant, Sézary syndrome. Another frequently encountered group includes CD30-positive lymphoproliferative disorders (CD30+ LPDs). In 7MM, the United States accounted for the highest number of incident cases of CTCL, which is 46% of the total incident population of CTCL in 7MM in 2023, as per DelveInsight. In the US, out of all stage-specific cases of CTCL, Stage-IA accounted for the highest number of cases, followed by Stage-IB and Stage-IIB cases in 2023. There is currently no approved first-line therapy for early-stage (I–IIA) cutaneous T-cell lymphoma, highlighting a significant unmet need in this patient population. Treatment decisions for patients with mycosis fungoides and Sézary syndrome, both types of CTCL, are influenced by factors such as the extent of skin involvement, the type of lesions, and whether metastasis is present. Therapies for mycosis fungoides focus on either localized skin treatment or systemic approaches, allowing many patients to achieve long-term remission and maintain normal lives. In contrast, Sézary syndrome, marked by systemic involvement, often requires systemic therapies, either alone or in combination, to improve long-term outcomes. TARGRETIN, ADCETRIS, POTELIGEO, ZOLINZA, and ISTODAX are approved by the US FDA for the treatment of Mycosis Fungoides and Sezary Syndrome. Other systemic therapies such as interferons (alfa and gamma), methotrexate, and other retinoids (acitretin and isotretinoin) also offer clinical benefits but have only been evaluated in small studies. As per DelveInsight analysis, the market size of CTCL in the 7MM is expected to cross USD 780 million by 2034. This growth is mainly driven by advancements in targeted therapies, rising awareness of rare cancers, and increasing research and development investments. The adoption of innovative treatments such as monoclonal antibodies and checkpoint inhibitors, coupled with improved diagnostic technologies, is anticipated to enhance market expansion. Additionally, a growing patient population and supportive regulatory policies will further bolster market growth. CTCL Pipeline Therapies and Companies HyBryte (SGX301): Soligenix KINSELBY (resminostat): 4SC AG Lacutamab: Innate Pharma Explore in-depth for a comprehensive understanding of the Cutaneous T-cell Lymphoma Clinical Trials Anaplastic Large Cell Lymphoma Market Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin lymphoma, characterized by large, irregular lymphoid cells that express the CD30 antigen. ALCL accounts for approximately 1% of all NHL cases and 16% of T-cell lymphomas. ALK-positive ALCL is associated with conditions such as HIV, mycosis fungoides, and pulmonary or inflammatory pseudotumors. In contrast, ALK-negative ALCL is more commonly observed in older individuals and is frequently linked to extranodal disease involvement. As per DelveInsight's analysis, ALCL has a slightly higher incidence in men compared to women. ALK-positive ALCL typically affects children and adolescents, with a median age of 30 years, while ALK-negative ALCL tends to affect older adults, with a median age of 54 years. ALK-positive ALCL carries a better prognosis, with 5-year survival rates of 70% to 90% , compared to 40% to 60% for ALK-negative ALCL. The treatment of ALCL varies based on its subtype and stage. Systemic ALCL is commonly addressed with chemotherapy regimens such as CHOP or CHOEP, showing improved outcomes in ALK-positive cases. The key drugs used for the treatment of anaplastic large cell lymphoma are – Pfizer's XALKORI and Takeda's ADCETRIS. For relapsed or refractory cases, brentuximab vedotin has proven effective. Primary cutaneous ALCL is typically managed through radiation, surgery, or chemotherapy and generally has a good prognosis. Breast implant-associated ALCL is treated by removing the implant, with radiation or chemotherapy added if the disease has spread. The ALCL market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of therapies, and raised awareness. Additionally, the ALCL market size is expected to increase due to an increasing diagnosed prevalent population, awareness about the subtype of ALCL (Breast implant-associated ALCL), and an increase in R&D activity, which would essentially boost the commercial success of emerging therapies. Anaplastic Large Cell Lymphoma Pipeline Therapies and Companies AUTO4: Autolus Therapeutics SGN-35T: Seagen To access a complete analysis of the anaplastic large cell lymphoma market, visit Anaplastic Large Cell Lymphoma Market Assessment Adult T-cell Leukemia/Lymphoma Market Adult T-cell Leukemia/Lymphoma (ATLL) is a rare and aggressive malignancy of mature T lymphocytes caused by infection with the human T-cell lymphotropic virus type 1 (HTLV-1). ATLL is classified into four clinical subtypes: acute, lymphomatous, chronic, and smoldering, each with distinct prognoses. The acute and lymphomatous forms are the most aggressive, with a median survival of less than a year without treatment. ATLL commonly affects adults aged 40–60 years and is associated with immunosuppression, hypercalcemia, and frequent involvement of skin, lymph nodes, and bone marrow. The global prevalence varies, but it is estimated that about 5–10% of individuals infected with HTLV-1 develop ATLL after decades of latency. Treatment for ATLL is challenging, as the disease presents with a wide range of clinical manifestations, from chronic to acute forms. First-line therapy often involves combination chemotherapy regimens, such as the CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) regimen, which has shown effectiveness in treating the aggressive forms of ATLL. For more refractory or relapsed cases, a bone marrow transplant may be considered as a curative option. Additionally, the use of denileukin diftitox, a fusion protein targeting CD25, has been approved for relapsed or refractory ATLL. Newer therapies are exploring the use of targeted agents, including histone deacetylase inhibitors (e.g., romidepsin) and lenalidomide, a potent immune-modulatory drug, to improve outcomes in patients with advanced disease. However, despite these options, ATLL treatment remains an area in urgent need of innovation to improve survival rates and quality of life for patients. The Adult T-cell leukemia/lymphoma market is expected to witness significant growth in the coming years, driven by advancements in diagnostics, therapies, and an increased understanding of the disease. Additionally, innovations in immunotherapies, including monoclonal antibodies, CAR-T cell therapies, and combination regimens, are expected to revolutionize the treatment landscape, offering hope for improved survival rates. Moreover, ongoing research into biomarkers and precision medicine will likely lead to better patient stratification and more effective treatment plans. Overall, the ATLL market is poised for expansion, attracting investments in research and development, clinical trials, and regulatory approvals to meet the growing need for better, more accessible therapies. Adult T-cell Leukemia/Lymphoma Pipeline Therapies and Companies Valemetostat Tosylate: Daiichi Sankyo BEAM-201: Beam Therapeutics Inc. Tolinapant: Astex Pharmaceuticals To delve into the adult T-cell leukemia/lymphoma market landscape in more detail, access the Adult T-cell Leukemia/Lymphoma Market Report Trending Oncology Reports Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLP

Victor Wembanyama went to a park in New York City and played 1-on-1 with fans on Saturday. He even lost a couple of games. Not in basketball, though. Wemby was playing chess. And this wasn't on a whim: He knows how to play and even brought his own chess set. Before the San Antonio Spurs left New York for a flight to Minnesota, Wembanyama put out the call on social media: “Who wants to meet me at the SW corner of Washington Square park to play chess? Im there,” Wembanyama wrote. It was 9:36 a.m. People began showing up almost immediately. Washington Square Park is a known spot for chess in New York — Bobby Fischer among others have famously played there, and it's been used for multiple movie scenes featuring the game. Wembanyama was there for an hour in the rain, from about 10-11 a.m. He played four games, winning two and losing two — he told Bleacher Report afterward that both of the losses were to professional chess players — before departing to catch the Spurs' flight. Wembanyama had been trying to get somewhere to play chess for the bulk of the team's time in New York — the Spurs played the Knicks on Christmas and won at Brooklyn on Friday night. The schedule never aligned, until Saturday morning. And even with bad weather, he bundled up to make it happen. He posed for photos with a couple of dozen people who showed up, braving a morning of cold rain to play chess with one of the NBA's biggest stars. “We need an NBA players only Chess tournament, proceeds go to the charity of choice of the winner,” he wrote on social media after his chess trip was over. Wembanyama is averaging 25.2 points and 10.1 rebounds this season, his second in the NBA after winning rookie of the year last season. The Spurs play at Minnesota on Sunday. AP NBA: https://apnews.com/hub/NBA

Providence, Oklahoma hope key players are back in Bahamas

Tomislav Ivisic scored a career-high 23 points to lead six players in double figures as No. 24 Illinois raced past visiting Chicago State 117-64 on Sunday in Champaign, Ill. Kylan Boswell also starred for the Fighting Illini (9-3) with an 18-point, 10-rebound, 10-assist triple-double. Dra Gibbs-Lawhorn added 16 points, while Kasparas Jakucionis contributed 14. Will Riley hit for 13 points and Morez Johnson Jr. came off the bench to net 11. Gabe Spinelli scored 20 points for the winless Cougars (0-15) and Noble Crawford added 15, but they just didn't have the scoring punch to stay with their Big Ten Conference opponent. Illinois outshot Chicago State 62.1 percent (41 of 66) to 37.3 percent (25 of 67) from the field and 45.5 percent (15 of 33) to 32.3 percent (10 of 31) from the 3-point line. The Cougars were also outrebounded 47-23. Illinois led for all but 24 seconds of the game, scoring basically at will. The Illini reaped a 28-4 advantage in free-throw attempts, drew 26 assists and earned a 48-16 advantage in points in the paint. In its last game before jumping into the bulk of its Big Ten schedule Thursday night at Oregon, Illinois wasted no time putting its stamp on the game. It carved out a double-figure edge at the 14:59 mark of the first half on Gibbs-Lawhorn's 3-pointer that made it 17-7 and simply kept expanding that lead. The margin reached 20 for the first time with 10:06 left when Ivisic drained a 3-pointer from the right wing for a 32-10 cushion. Johnson's foul shot with 3:43 remaining increased the advantage to 30 at 48-18, and Jake Davis' 3-pointer from the corner with a second on the clock gave the Illini a 60-24 cushion at halftime. Boswell's short jumper with 18:22 left in the game built Illinois' first 40-point advantage at 65-24. Riley splashed a 3-pointer with 9:57 remaining to up the lead to 50 at 93-43. Davis made another 3-pointer at the 7:59 mark to get the Illini to the 100-point threshold. They led by as many as 58 points in the final two minutes. --Field Level Media

Nitish Kumar to lead NDA in state polls: Bihar BJPLetters for Dec. 12: Regional Greenhouse Gas Initiative membership benefits Virginia

DNA breakthrough helps police ID skull found in 1988 cold caseMUMBAI: A 53-year-old Andheri resident working in an insurance firm was duped of ₹ 5.70 crore in an online share trading cyber fraud. The professional has been transferring money from September in an app he was asked to download under the assumption that he was investing. A case was registered by cyber police on Saturday in connection with the matter. According to the police, the complainant works in an insurance firm. On September 12, he allegedly received a WhatsApp message from someone who went by Aman Malik. Malik offered guidance on stock market investment promising high returns. The victim expressed interest in this and received a call from an unknown person who claimed to be a representative of an investment firm. He then sent him a link to join a WhatsApp group which was named ‘Y21-VIP-WTIC World Top Investor Competition’, where Malik was the group admin. Malik sent messages in the group with tips and guides to invest. Other members of the group allegedly posted screenshots showing they received huge returns on their investments. Convinced by the screenshots and lured by high returns, the complainant decided to invest through the firm and downloaded an app from a link Malik sent. He transferred ₹ 5 lakh through the app and in two days, he saw a profit of ₹ 70 thousand and began trusting the app, said a police officer. From October 18 to November 8, he transferred a total ₹ 5.70 crore in over 20 transactions to the scammers. On November 11, when he tried to withdraw money, he was asked to pay more under the pretext of processing fee among others. He found this suspicious and contacted cyber helpline number. An FIR was registered in the West Cyber police station on Saturday and investigation is underway, said the officer.